ICHNOS SCIENCES ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD TO INFORM RESEARCH AND DEVELOPMENT STRATEGY IN IMMUNO-ONCOLOGY
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
📰 Ichnos Sciences News
Page 5 - Ichnos Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ichnos Sciences. Real-time updates on events, politics, business and more.
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 1, 2022--
Source: kulr8.com
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
03.01.2022 - CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) - Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular ... Seite 1
United Kingdom Ben Zeskind Rimma Steinhertz Alliance Management Portfolio Program Management Johnson Pharmaceutical Research Development
Source: wallstreet-online.de
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
United Kingdom Ben Zeskind Susana Noonan Rebecca Kusko Rimma Steinhertz Portfolio Program Management
Source: apnews.com
Stocks in news: ICICI Bank, Tata Steel, TVS Motor, Cipla and more
Stocks in news: ICICI Bank, PNB, Tata Steel, TVS Motor, Cipla, Prestige Estates and more
Sun Pharma Glenmark Pharma Bajaj Finserv Sun Pharmaceutical Industries Prestige Group Punjab National Bank
Source: businesstoday.in
Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody
Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody  ·         Almirall is Granted Exclusive Global Rights to Develop and Commercialize ISB 880 for Use in Autoimmune Diseases NEW YORK, US...
New York United States Comunidad Autonoma De Cataluna Cyril Konto Karl Ziegelbauer Ichnos Sciences Inc
Source: pharmiweb.com
ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY
/PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A....
Source: prnewswire.com
ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Source: apnews.com
ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY
/PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A....
Source: prnewswire.com
Glenmark's subsidiary Ichnos Sciences inks agreement with Almirall
Almirall is granted exclusive global rights to develop and commercialise ISB 880 for use in autoimmune diseases
Source: biospectrumindia.com